Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Finkel

Showing results (1661-1670 of 2,011) with videos related to

Pageof 202
Sort By:
Plos One|May 5, 2012
Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical studyRichard S Finkel, Thomas O Crawford, Kathryn J Swoboda, et al.
Cephalalgia : an International Journal of Headache|March 22, 2024
Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injuryHåkan Ashina, Hans-Christoph Diener, Cristina Tassorelli, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World DataCostanza Cutrona, Roberto de Sanctis, Giorgia Coratti, et al.
Nature|March 16, 2017
Root microbiota drive direct integration of phosphate stress and immunityGabriel Castrillo, Paulo José Pereira Lima Teixeira, Sur Herrera Paredes, et al.
Human Molecular Genetics|November 1, 1996
Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophyE M McNally, D Duggan, J R Gorospe, et al.
Lancet (London, England)|December 13, 2016
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation studyRichard S Finkel, Claudia A Chiriboga, Jiri Vajsar, et al.
Circulation|August 13, 2003
Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet SubstudyVictor L Serebruany, Alexander H Glassman, Alex I Malinin, et al.
The Lancet. Child & Adolescent Health|June 5, 2021
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation studyRichard S Finkel, Claudia A Chiriboga, Jiri Vajsar, et al.
Nature|May 12, 2021
SARS-CoV-2 uses a multipronged strategy to impede host protein synthesisYaara Finkel, Avi Gluck, Aharon Nachshon, et al.
Cell Metabolism|July 5, 2011
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signalingHariom Yadav, Celia Quijano, Anil K Kamaraju, et al.
Pageof 202

Showing results (1661-1670 of 2,011) with videos related to

Sort By:
Pageof 202
Plos One|May 5, 2012
Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical studyRichard S Finkel, Thomas O Crawford, Kathryn J Swoboda, et al.
Cephalalgia : an International Journal of Headache|March 22, 2024
Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injuryHåkan Ashina, Hans-Christoph Diener, Cristina Tassorelli, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World DataCostanza Cutrona, Roberto de Sanctis, Giorgia Coratti, et al.
Nature|March 16, 2017
Root microbiota drive direct integration of phosphate stress and immunityGabriel Castrillo, Paulo José Pereira Lima Teixeira, Sur Herrera Paredes, et al.
Human Molecular Genetics|November 1, 1996
Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophyE M McNally, D Duggan, J R Gorospe, et al.
Lancet (London, England)|December 13, 2016
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation studyRichard S Finkel, Claudia A Chiriboga, Jiri Vajsar, et al.
Circulation|August 13, 2003
Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet SubstudyVictor L Serebruany, Alexander H Glassman, Alex I Malinin, et al.
The Lancet. Child & Adolescent Health|June 5, 2021
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation studyRichard S Finkel, Claudia A Chiriboga, Jiri Vajsar, et al.
Nature|May 12, 2021
SARS-CoV-2 uses a multipronged strategy to impede host protein synthesisYaara Finkel, Avi Gluck, Aharon Nachshon, et al.
Cell Metabolism|July 5, 2011
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signalingHariom Yadav, Celia Quijano, Anil K Kamaraju, et al.
Pageof 202